"Clozapine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.
Descriptor ID |
D003024
|
MeSH Number(s) |
D03.633.300.240.220
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clozapine".
Below are MeSH descriptors whose meaning is more specific than "Clozapine".
This graph shows the total number of publications written about "Clozapine" by people in this website by year, and whether "Clozapine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clozapine" by people in Profiles.
-
Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: A systematic review. Medicine (Baltimore). 2021 Nov 12; 100(45):e27694.
-
Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem. 2004 Feb; 11(3):297-312.
-
Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001 Dec; 21(6):603-7.
-
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. J Clin Psychopharmacol. 2001 Aug; 21(4):398-407.